The U.S. Drug Enforcement Administration is about to make the biggest marijuana reform move in over half a century, with a proposed reclassification from Schedule I to Schedule III on the list of controlled substances, the Associated Press reported Tuesday, citing five unnamed sources. If ultimately accomplished, the rescheduling would be a formal recognition by the U.S. government that marijuana has medical value and should be legally available to patients.
The next step, according to the AP, is for the White House Office of Management and Budget to formally sign off on the proposed rule, after which a public comment period would ensue before the DEA publishes a final rule.
The step is a near-culmination of a process kickstarted by President Joe Biden in October 2022, when he ordered his administration to begin a review of marijuana’s classification as a federally prohibited drug. Last summer, the U.S. Food and Drug Administration issued a formal recommendation to the DEA that cannabis be moved to Schedule III, citing medical benefits of cannabis, but the DEA has remained mum about its plans and timeline on whether it would accept the recommendation.
That’s led to endless speculation in the marijuana industry for months as to when the DEA would make any formal announcement, which it still has not. The AP report that a decision has been reached was based on five sources who were all granted anonymity.
The DEA declined to comment on the AP report and referred Green Market Report to the Department of Justice. The DOJ could not be reached immediately for comment.
While rescheduling would mark a historic shift for cannabis legalization advocates, it’s also not the entire ballgame. Many activists are far from content with the reclassification, because it leaves in place many state laws that still criminalize marijuana, and also leaves in place plenty of business hurdles.
The biggest and most immediate benefit would be the effective elimination of 280E, the irksome portion of the federal tax code that prohibits state-legal cannabis companies from claiming business tax deductions. The provision routinely costs businesses millions each year, and not having to comply with that would be a financial boon to the entire industry.
But rescheduling would also leave in place laws that prohibit interstate commerce, since none of the state-legal marijuana companies are actually legally qualified to traffic in Schedule III substances. That’s a domain reserved for major pharmaceutical companies which deal in medical-grade Tylenol with codeine, ketamine, anabolic steroids, and other Schedule III drugs.
It also would leave unsettled the legal tension between federal law and state marijuana markets, particularly recreational marijuana markets. That’s because Schedule III drugs are accepted as having medical use, but the drugs themselves remain very heavily regulated and are not available for over-the-counter purchase, as adult-use cannabis is in much of the country.
Some legal experts have suggested that a new Cole Memo-style guidance from the Department of Justice could rectify that, at least temporarily. The Cole Memo was a policy document issued by the DOJ in 2013 after Colorado and Washington state legalized recreational marijuana, outlining certain standards by which the DOJ would remain hands-off and not raid state-licensed cannabis companies. But the Cole Memo and other cannabis policy documents were rescinded during the Trump administration in 2018 by then-Attorney General Jeff Sessions.
Attorney Shane Pennington recently cautioned, however, that even a proposed rule from the DEA only launches a lengthy process, which he predicted will also involve litigation by cannabis opponents who will be intent on derailing the rescheduling process.
“If you look back at recent times there have been hearings, just the pre-conference litigation … filled 15 volumes of records and took two years to complete,” Pennington told Green Market Report earlier this month. “Then you had more years of (administrative law judge) hearings. Then you had litigation in federal court. And if you think this isn’t going to get litigated, I don’t know what you’re smoking.”
“My point is simply, no matter how you slice it, we have a very long way to go,” Pennington said.
Regardless, the rescheduling move has been hotly anticipated for months by the U.S. cannabis industry, much of which sees the shift as a gateway to additional capital and investment dollars.
The post Report: DEA poised to move cannabis to Schedule III appeared first on Green Market Report.
KahliBuds Tea News 
Leave a comment